Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
LOL, THIS IS PATHETIC
$SGMD's Sriracha Seasoning Stixs could bring in $200-300K a month, they flavors are endless and foodies will love them.
$SGMD already makes $5 Million in Revenue, has ZERO TOXIC DEBT, 50M Float
And the Sriracha product hasn't even shipped yet. Sriracha Seasoning Sticks will be a culinary cult hit just like Sriracha sauce.
https://www.facebook.com/huyfongofficial/?hc_ref=SEARCH&fref=nf
http://www.highsnobiety.com/2017/02/21/sriracha-stix/
http://coolmaterial.com/food-drink/sriracha-seasoning-sticks/
http://www.blessthisstuff.com/stuff/culture/food/sriracha-seasoning-stix/
http://www.refinery29.com/2017/02/141156/stiiracha-seasoning-stix
http://www.popsugar.com/food/Sriracha-Seasoning-Stix-43182340
http://www.msn.com/en-us/foodanddrink/foodnews/these-sriracha-seasoning-sticks-will-change-the-way-you-cook/ar-AAnb5ey
http://www.dudeiwantthat.com/food/sriracha-seasoning-stix.asp
https://www.simplemost.com/sriracha-seasoning-sticks-meat-kitchen/
http://www.likecool.com/Sriracha_Seasoning_Stix--Gadget--Gear.html
http://dish.allrecipes.com/sriracha-stix/
http://www.travelandleisure.com/syndication/sriracha-seasoning-stix
http://www.thatsnerdalicious.com/spicy-foods/sriracha-seasoning-stix/
http://www.meatpoultry.com/articles/news_home/Business/2016/10/Sugarmade_unveils_Sriracha_Sea.aspx?ID=%7B49A541C5-37C8-439F-BB12-5FF0E2973F98%7D&cck=1
http://www.wideopeneats.com/sriracha-stix-are-here-and-we-cant-wait-to-try-them/
$SGMD'S Sriracha Seasoning Stixs could bring in $200-300K a month, they flavors are endless and foodies will love them.
$SGMD already makes $5 Million in Revenue, has ZERO TOXIC DEBT, 50M Float
And the Sriracha product hasn't even shipped yet. Sriracha Seasoning Sticks will be a culinary cult hit just like Sriracha sauce.
https://www.facebook.com/huyfongofficial/?hc_ref=SEARCH&fref=nf
http://www.highsnobiety.com/2017/02/21/sriracha-stix/
http://coolmaterial.com/food-drink/sriracha-seasoning-sticks/
http://www.blessthisstuff.com/stuff/culture/food/sriracha-seasoning-stix/
http://www.refinery29.com/2017/02/141156/stiiracha-seasoning-stix
http://www.popsugar.com/food/Sriracha-Seasoning-Stix-43182340
http://www.msn.com/en-us/foodanddrink/foodnews/these-sriracha-seasoning-sticks-will-change-the-way-you-cook/ar-AAnb5ey
http://www.dudeiwantthat.com/food/sriracha-seasoning-stix.asp
https://www.simplemost.com/sriracha-seasoning-sticks-meat-kitchen/
http://www.likecool.com/Sriracha_Seasoning_Stix--Gadget--Gear.html
http://dish.allrecipes.com/sriracha-stix/
http://www.travelandleisure.com/syndication/sriracha-seasoning-stix
http://www.thatsnerdalicious.com/spicy-foods/sriracha-seasoning-stix/
http://www.meatpoultry.com/articles/news_home/Business/2016/10/Sugarmade_unveils_Sriracha_Sea.aspx?ID=%7B49A541C5-37C8-439F-BB12-5FF0E2973F98%7D&cck=1
http://www.wideopeneats.com/sriracha-stix-are-here-and-we-cant-wait-to-try-them/
These Sriracha Seasoning Stixs could bring in $200-300K a month, they flavors are endless and foodies will love them.
And the Sriracha product hasn't even shipped yet. Sriracha Seasoning Sticks will be a culinary cult hit just like Sriracha sauce.
https://www.facebook.com/huyfongofficial/?hc_ref=SEARCH&fref=nf
http://www.highsnobiety.com/2017/02/21/sriracha-stix/
http://coolmaterial.com/food-drink/sriracha-seasoning-sticks/
http://www.blessthisstuff.com/stuff/culture/food/sriracha-seasoning-stix/
http://www.refinery29.com/2017/02/141156/stiiracha-seasoning-stix
http://www.popsugar.com/food/Sriracha-Seasoning-Stix-43182340
http://www.msn.com/en-us/foodanddrink/foodnews/these-sriracha-seasoning-sticks-will-change-the-way-you-cook/ar-AAnb5ey
http://www.dudeiwantthat.com/food/sriracha-seasoning-stix.asp
https://www.simplemost.com/sriracha-seasoning-sticks-meat-kitchen/
http://www.likecool.com/Sriracha_Seasoning_Stix--Gadget--Gear.html
http://dish.allrecipes.com/sriracha-stix/
http://www.travelandleisure.com/syndication/sriracha-seasoning-stix
http://www.thatsnerdalicious.com/spicy-foods/sriracha-seasoning-stix/
http://www.meatpoultry.com/articles/news_home/Business/2016/10/Sugarmade_unveils_Sriracha_Sea.aspx?ID=%7B49A541C5-37C8-439F-BB12-5FF0E2973F98%7D&cck=1
http://www.wideopeneats.com/sriracha-stix-are-here-and-we-cant-wait-to-try-them/
pathetic volume
slow bleed lower
Nice to see investors collecting some profits, way to go.
The pop is over from the CC for Thursday night, hopefully there is more coming from management.
$NPHC News on NBC and Analyst Coverage pushes pps UP 20% this week, room to run higher.
$NPHC analyst coverage and NBC News story pushing share price up 20% this week, nice play with room to run higher.
$NPHC climbing on recent NBC News story and analyst coverage with a .10pps valuations. Remember, they are all gambles, know when to get in, and get out.
up 20% this week $NPHC, on NBC News last week, analyst coverage out yesterday with a .10pps valuation.
http://www.tinyurl.com/nyloxinNBC
$NPHC •The Company was recently featured in NBC news. The interview is here: www.tinyurl.com/nyloxinNBC
http://www.tinyurl.com/nyloxinNBC
$NPHC •The Company was recently featured in NBC news. The interview is here: www.tinyurl.com/nyloxinNBC
http://www.tinyurl.com/nyloxinNBC
$NPHC Summary of Our Research Findings
•We begin coverage of Nutra Pharma, Corp. with a Buy recommendation and a price target of $0.10 per share.
•Nutra Pharma is in the process of introducing cobra toxin-based therapies for human and pet pain management markets and additionally has therapeutic drug development opportunities relative to HIV and MS.
•OTC sales are being driven by retail expansion and DRTV programs.
•The worldwide pain management market is of significant size and is undergoing dramatic change as physicians significantly curtail narcotic prescriptions. This is creating new opportunities for innovative pain treatment therapies and products. There is much focus on this sector.
•The Company was recently featured in NBC news. The interview is here: www.tinyurl.com/nyloxinNBC
•While we do not believe it to be the near term market opportunity for the Company, it also has a strong pipeline of possible therapies for autoimmune diseases and HIV. Orphan drug status as been granted for RPI-78M.
•In our opinion, this is an innovative company with a therapy that is exciting and could capture the imagination of risk-averse investors, yielding a significantly higher, stock price.
Nutra Pharma Corp. (OTCQB:NPHC)
$NPHC up 20%- Summary of Our Research Findings
•We begin coverage of Nutra Pharma, Corp. with a Buy recommendation and a price target of $0.10 per share.
•Nutra Pharma is in the process of introducing cobra toxin-based therapies for human and pet pain management markets and additionally has therapeutic drug development opportunities relative to HIV and MS.
•OTC sales are being driven by retail expansion and DRTV programs.
•The worldwide pain management market is of significant size and is undergoing dramatic change as physicians significantly curtail narcotic prescriptions. This is creating new opportunities for innovative pain treatment therapies and products. There is much focus on this sector.
•The Company was recently featured in NBC news. The interview is here: www.tinyurl.com/nyloxinNBC
•While we do not believe it to be the near term market opportunity for the Company, it also has a strong pipeline of possible therapies for autoimmune diseases and HIV. Orphan drug status as been granted for RPI-78M.
•In our opinion, this is an innovative company with a therapy that is exciting and could capture the imagination of risk-averse investors, yielding a significantly higher, stock price.
Nutra Pharma Corp. (OTCQB:NPHC)
http://globalsmallcaps.com/2017/02/14/nutra-pharma-corp/
$NPHC up 20% on Analyst Coverage. CORAL SPRINGS, FL--(Marketwired - Feb 22, 2017) - Nutra Pharma Corporation ( OTCQB : NPHC ), a biotechnology company developing drugs for the treatment of Multiple Sclerosis and HIV that also markets Nyloxin® and Pet Pain-Awayâ„¢ in the over-the-counter (OTC) pain management market, announced today that Global Small Caps has initiated coverage of the Company including operations and overall shareholder value.
The report is available at: http://tinyurl.com/NPHCreport
https://finance.yahoo.com/news/global-small-caps-initiates-coverage-133000273.html
$NPHC up 20% on Analyst Coverage. CORAL SPRINGS, FL--(Marketwired - Feb 22, 2017) - Nutra Pharma Corporation ( OTCQB : NPHC ), a biotechnology company developing drugs for the treatment of Multiple Sclerosis and HIV that also markets Nyloxin® and Pet Pain-Awayâ„¢ in the over-the-counter (OTC) pain management market, announced today that Global Small Caps has initiated coverage of the Company including operations and overall shareholder value.
The report is available at: http://tinyurl.com/NPHCreport
https://finance.yahoo.com/news/global-small-caps-initiates-coverage-133000273.html
$NPHC up 20% on Analyst Coverage. CORAL SPRINGS, FL--(Marketwired - Feb 22, 2017) - Nutra Pharma Corporation ( OTCQB : NPHC ), a biotechnology company developing drugs for the treatment of Multiple Sclerosis and HIV that also markets Nyloxin® and Pet Pain-Awayâ„¢ in the over-the-counter (OTC) pain management market, announced today that Global Small Caps has initiated coverage of the Company including operations and overall shareholder value.
The report is available at: http://tinyurl.com/NPHCreport
https://finance.yahoo.com/news/global-small-caps-initiates-coverage-133000273.html
Grab what yah can, shares are cheap but not for LONG
The Pain Management Market – Huge Unsatisfied Demand
According to the World Health Organization, the number of people suffering worldwide from chronic pain is rising at a dramatic rate. Within the U.S. alone there are at least 116 million people looking for solutions for chronic pain management. According to other sources, at least one in five people outside of the United States also suffers from severe pain. This places the market worldwide at over one billion patients.
An additional factor contributing to this growing market is the vast rise in the world’s geriatric population, which is quickly emerging as the key growth driver for the global pain management market. With the global population of geriatrics expected to rise to more than two billion over the next ten years, and as conditions, such as arthritis and diabetic nerve damage continue to grow at nearly unchecked rates, it is clear that the market for pain treatments will be robust for many years to come.
No part of the worldwide market, however, compares to the dramatic growth rates being realized in the United States. Americans are much more likely to seek pain treatment than are almost any other population. In fact, with only 5% of the world’s population, the American pain management market accounts for over half of the worldwide market as of the end of 2015.
The pain management market is especially exciting within the United States, not only because Americans seek treatment at much higher rates, but also because physicians are radically curtailing prescribing powerful opiate painkillers to patients. The North American opioid market is valued at over $11 billion per year with the vast majority of these revenues being derived via pain relief prescriptions, as is outlined in Exhibit One. As doctors cut back on writing prescriptions, patients are more active than ever in seeking alternative treatments.
$NPHC DD- The Pain Management Market – Huge Unsatisfied Demand
According to the World Health Organization, the number of people suffering worldwide from chronic pain is rising at a dramatic rate. Within the U.S. alone there are at least 116 million people looking for solutions for chronic pain management. According to other sources, at least one in five people outside of the United States also suffers from severe pain. This places the market worldwide at over one billion patients.
An additional factor contributing to this growing market is the vast rise in the world’s geriatric population, which is quickly emerging as the key growth driver for the global pain management market. With the global population of geriatrics expected to rise to more than two billion over the next ten years, and as conditions, such as arthritis and diabetic nerve damage continue to grow at nearly unchecked rates, it is clear that the market for pain treatments will be robust for many years to come.
No part of the worldwide market, however, compares to the dramatic growth rates being realized in the United States. Americans are much more likely to seek pain treatment than are almost any other population. In fact, with only 5% of the world’s population, the American pain management market accounts for over half of the worldwide market as of the end of 2015.
The pain management market is especially exciting within the United States, not only because Americans seek treatment at much higher rates, but also because physicians are radically curtailing prescribing powerful opiate painkillers to patients. The North American opioid market is valued at over $11 billion per year with the vast majority of these revenues being derived via pain relief prescriptions, as is outlined in Exhibit One. As doctors cut back on writing prescriptions, patients are more active than ever in seeking alternative treatments.
$NPHC DD- The Pain Management Market – Huge Unsatisfied Demand
According to the World Health Organization, the number of people suffering worldwide from chronic pain is rising at a dramatic rate. Within the U.S. alone there are at least 116 million people looking for solutions for chronic pain management. According to other sources, at least one in five people outside of the United States also suffers from severe pain. This places the market worldwide at over one billion patients.
An additional factor contributing to this growing market is the vast rise in the world’s geriatric population, which is quickly emerging as the key growth driver for the global pain management market. With the global population of geriatrics expected to rise to more than two billion over the next ten years, and as conditions, such as arthritis and diabetic nerve damage continue to grow at nearly unchecked rates, it is clear that the market for pain treatments will be robust for many years to come.
No part of the worldwide market, however, compares to the dramatic growth rates being realized in the United States. Americans are much more likely to seek pain treatment than are almost any other population. In fact, with only 5% of the world’s population, the American pain management market accounts for over half of the worldwide market as of the end of 2015.
The pain management market is especially exciting within the United States, not only because Americans seek treatment at much higher rates, but also because physicians are radically curtailing prescribing powerful opiate painkillers to patients. The North American opioid market is valued at over $11 billion per year with the vast majority of these revenues being derived via pain relief prescriptions, as is outlined in Exhibit One. As doctors cut back on writing prescriptions, patients are more active than ever in seeking alternative treatments.
•We begin coverage of Nutra Pharma, Corp. with a Buy recommendation and a price target of $0.10 per share.
•Nutra Pharma is in the process of introducing cobra toxin-based therapies for human and pet pain management markets and additionally has therapeutic drug development opportunities relative to HIV and MS.
•OTC sales are being driven by retail expansion and DRTV programs.
•The worldwide pain management market is of significant size and is undergoing dramatic change as physicians significantly curtail narcotic prescriptions. This is creating new opportunities for innovative pain treatment therapies and products. There is much focus on this sector.
•The Company was recently featured in NBC news. The interview is here: www.tinyurl.com/nyloxinNBC
•While we do not believe it to be the near term market opportunity for the Company, it also has a strong pipeline of possible therapies for autoimmune diseases and HIV. Orphan drug status as been granted for RPI-78M.
•In our opinion, this is an innovative company with a therapy that is exciting and could capture the imagination of risk-averse investors, yielding a significantly higher, stock price.
(((( $nphc research report out ))) •We begin coverage of Nutra Pharma, Corp. with a Buy recommendation and a price target of $0.10 per share.
•Nutra Pharma is in the process of introducing cobra toxin-based therapies for human and pet pain management markets and additionally has therapeutic drug development opportunities relative to HIV and MS.
•OTC sales are being driven by retail expansion and DRTV programs.
•The worldwide pain management market is of significant size and is undergoing dramatic change as physicians significantly curtail narcotic prescriptions. This is creating new opportunities for innovative pain treatment therapies and products. There is much focus on this sector.
•The Company was recently featured in NBC news. The interview is here: www.tinyurl.com/nyloxinNBC
•While we do not believe it to be the near term market opportunity for the Company, it also has a strong pipeline of possible therapies for autoimmune diseases and HIV. Orphan drug status as been granted for RPI-78M.
•In our opinion, this is an innovative company with a therapy that is exciting and could capture the imagination of risk-averse investors, yielding a significantly higher, stock price.
$NPHC analysis report out, price target of .10pps
$NPHC-The Company was recently featured in NBC news. The interview is here: www.tinyurl.com/nyloxinNBC
$NPHC-The Company was recently featured in NBC news. The interview is here: www.tinyurl.com/nyloxinNBC
More great news out on SGMD- Sugarmade Plans Leadership in Cannabis Active Packaging
https://www.otcmarkets.com/stock/SGMD/news/Sugarmade-Plans-Leadership-in-Cannabis-Active-Packaging?id=151551&b=y
More great news out on SGMD- Sugarmade Plans Leadership in Cannabis Active Packaging
https://www.otcmarkets.com/stock/SGMD/news/Sugarmade-Plans-Leadership-in-Cannabis-Active-Packaging?id=151551&b=y
price target of $0.10 per share. http://globalsmallcaps.com/2017/02/14/nutra-pharma-corp/
$nphc price target of $0.10 per share.
http://globalsmallcaps.com/2017/02/14/nutra-pharma-corp/
Great coverage on $NPHC undervalued Bio Play
http://globalsmallcaps.com/2017/02/14/nutra-pharma-corp/
Slow and steady, .17 will be taken out this week.
Update coming-$PPJE-Closes Billing Contracts In California Workers Compensation Compounding Pharmacy Billing
https://www.otcmarkets.com/stock/PPJE/news/PPJ-Healthcare-Enterprises-Inc--Closes-Billing-Contracts-In-California-Workers-Compensation-Compounding-Pharmacy-Billing?id=147340&b=y
Update coming on $PPJE- Closes Billing Contracts In California Workers Compensation Compounding Pharmacy Billing
https://www.otcmarkets.com/stock/PPJE/news/PPJ-Healthcare-Enterprises-Inc--Closes-Billing-Contracts-In-California-Workers-Compensation-Compounding-Pharmacy-Billing?id=147340&b=y
CEO said "update, news" coming, So I'm guessing some progress on one of the old news releases, just bring attention for new investors.
Watch for up on this- $PPJE Executes Contracts for Medical Marijuana Testing
https://www.otcmarkets.com/stock/PPJE/news/PPJ-Executes-Contracts-for-Medical-Marijuana-Testing?id=125653&b=y
$PPJE Executes Contracts for Medical Marijuana Testing
https://www.otcmarkets.com/stock/PPJE/news/PPJ-Executes-Contracts-for-Medical-Marijuana-Testing?id=125653&b=y
$PPJE Healthcare Enterprises Inc. Closes Billing Contracts In California Workers Compensation Compounding Pharmacy Billing
https://www.otcmarkets.com/stock/PPJE/news/PPJ-Healthcare-Enterprises-Inc--Closes-Billing-Contracts-In-California-Workers-Compensation-Compounding-Pharmacy-Billing?id=147340&b=y